Efficacy of pulmonary insulin delivery in diabetic rats: Use of a model-based approach in the evaluation of insulin powder formulations

Journal of Controlled Release

Volumn 127, Issue 3, 2008, Pages 257-266

  Amidi, Maryam ^a   Krudys, Kevin M ^b   Snel, Cor J ^a   Crommelin, Daan J A ^a   Della Pasqua, Oscar E ^b,c   Hennink, Wim E ^a   Jiskoot, Wim ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Insulin; N Trimethyl chitosan microparticles; NONMEM; PK PD modeling; Pulmonary delivery; Supercritical carbon dioxide

Indexed keywords

N-TRIMETHYL CHITOSAN MICROPARTICLES; PK-PD MODELING; PULMONARY DELIVERY; SUPERCRITICAL CARBON DIOXIDE;

CHITOSAN; DRUG DELIVERY; MEDICAL PROBLEMS; NITROGEN COMPOUNDS; RATS;

INSULIN;

DEXTRAN; DRUG CARRIER; INSULIN; N TRIMETHYLCHITOSAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HISTOPATHOLOGY; INSULIN SENSITIVITY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL FLUID;

ANIMALS; BLOOD GLUCOSE; CHITOSAN; DEXTRANS; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION ROUTES; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; MALE; MODELS, BIOLOGICAL; POWDERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 42049116543     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.01.019     Document Type: Article

References (53)

1. Skyler J.S., Cefalu W.T., Kourides I.A., Landschulz W.H., Balagtas C.C., Cheng S.L., and Gelfand R.A. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357 (2001) 331-335
2. Mandal T.K. Inhaled insulin for diabetes mellitus. Am. J. Health-Syst. Pharm. 62 (2005) 1359-1364
3. Ma Z., Lim T.M., and Lim L.Y. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int. J. Pharm. 293 (2005) 271-280
4. Cui F., Shi K., Zhang L., Tao A., and Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114 (2006) 242-250
5. Fernandez-Urrusuno R., Calvo P., Remunan-Lopez C., Vila-Jato J.L., and Alonso M.J. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 16 (1999) 1576-1581
6. Patton J.S., Bukar J.G., and Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 43 (2004) 781-801
7. Dailey G. Developing a pulmonary insulin delivery system for patients with diabetes. Clin. Ther. 29 (2007) 1271-1283 (Spec No)
8. Ghosh S., and Collier A. Inhaled insulins. Postgrad. Med. J. 83 (2007) 178-181
9. Muchmore D.B., and Gates J.R. Inhaled insulin delivery - where are we now?. Diabetes Obes. Metab. 8 (2006) 634-642
10. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6 (2007) 67-74
11. Patton J.S. Mechanisms of macromolecules absorption by the lungs. Adv. Drug Deliv. Rev. 19 (1996) 3-36
12. Newman S.P., Hollingworth A., and Clark A.R. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int. J. Pharm. 102 (1994) 127-132
13. Patton J.S., Fishburn C.S., and Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1 (2004) 338-344
14. Molina R.M., and Brain J.D. In vivo comparison of cat alveolar and pulmonary intravascular macrophages: phagocytosis, particle clearance, and cytoplasmic motility. Exp. Lung Res. 33 (2007) 53-70
15. Todo H., Okamoto H., Iida K., and Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int. J. Pharm. 220 (2001) 101-110
16. Hussain A., Majumder Q.H., and Ahsan F. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm. Res. 23 (2006) 138-147
17. Hussain A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94 (2004) 15-24
18. Suarez S., Garcia-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., and Hickey A.J. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm. Res. 18 (2001) 1677-1684
19. Todo H., Iida K., Okamoto H., and Danjo K. Improvement of insulin absorption from intratracheally administrated dry powder prepared by supercritical carbon dioxide process. J. Pharm. Sci. 92 (2003) 2475-2486
20. Woods T.C., Zhang B., Mercogliano F., and Dinh S.M. Response of the lung to pulmonary insulin dosing in the rat model and effects of changes in formulation. Diabetes Technol. Ther. 7 (2005) 516-524
21. Van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Verhoef J.C., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 28 (2003) 1400-1408
22. Vila A., Sanchez A., Janes K., Behrens I., Kissel T., Vila Jato J.L., and Alonso M.J. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57 (2004) 123-131
23. Grenha A., Seijo B., and Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25 (2005) 427-437
24. A. Grenha, C. Remunan-Lopez, E.L. Carvalho, B. Seijo, Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins, Eur. J. Pharm. Biopharm. (in press) doi:10.1016/j.ejpb.2007.10.017.
25. Thanou M., Verhoef J.C., Verheijden J.H.M., and Junginger H.E. Intestinal absorption of octeriotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J. Pharm. Sci. 89 (2000) 951-957
26. Hamman J.H., Stander M., and Kotzé A.F. Effect of the degree of quaternization of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int. J. Pharm. 232 (2002) 235-242
27. Amidi M., Romeijn S.G., Borchard G., Junginger H.E., Hennink W.E., and Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J. Control. Release 111 (2006) 107-116
28. Hamman J.H., Schultz C.M., and Kotzé A.F. N-trimethyl chitosan chloride: optimum degree of quaternization for drug absorption enhancement across epithelial cells. Drug Dev. Ind. Pharm. 29 (2003) 161-172
29. Snyman D., Hamman J.H., and Kotze A.F. Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug Dev. Ind. Pharm. 29 (2003) 61-69
30. Elvassore N., Bertucco A., and Caliceti P. Production of insulin-loaded poly(ethylene glycol)/poly(l-lactide) (PEG/PLA) nano-particles by gas antisolvent techniques. J. Pharm. Sci. 90 (2001) 1628-1636
31. Jovanovic N., Bouchard A., Hofland G.W., Witkamp G.J., Crommelin D.J.A., and Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res. 21 (2004) 1955-1969
32. Danhof M., de Jongh J., De Lange E.C., Della Pasqua O., Ploeger B.A., and Voskuyl R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 357-400
33. Jiang X., van der Horst A., van Steenbergen M.J., Akeroyd N., van Nostrum C.F., Schoenmakers P.J., and Hennink W.E. Molar-mass characterization of cationic polymers for gene delivery by aqueous size-exclusion chromatography. Pharm. Res. 23 (2006) 595-603
34. Sieval A.B., Thanou M., Kotzé A.F., Verhoef J.C., Brussee J., and Junginger H.E. Preparation and NMR-characterisation of highly substituted N-trimethyl chitosan chloride. Carbohydr. Polym. 36 (1998) 157-165
35. Amidi M., Pellikaan H.C., de Boer A.H., Crommelin D.J., Hennink W.E., and Jiskoot W. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur. J. Pharm. Biopharm. 68 (2008) 191-200
36. Pérez de Diego Y., Pellikaan H.C., Wubbolts F.E., Borchard G., Witkamp G.J., and Jansens P.J. Opening new operating windows for polymer and protein micronisation using the PCA process. J. Supercrit. Fluids 36 (2006) 216-224
37. Bergman R.N., Ider Y.Z., Bowden C.R., and Cobelli C. Quantitative estimation of insulin sensitivity. Am. J. Physiol. 236 (1979) E667-E677
38. Beal S.L., and Sheiner L.B. NONMEM User Guide (1992), NONMEM Project Group, Univ. of California San Francisco, San Francisco, CA
39. Tabata Y., and Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9 4 (1988) 356-362
40. Makino K., Yamamoto N., Higuchi K., Harada N., Ohshima H., and Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Col. Surf. B 27 (2003) 33-39
41. Chono S., Tanino T., Seki T., and Morimoto K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 14 (2006) 557-566
42. Gopalakrishnan M., Suarez S., Hickey A.J., and Gobburu J.V. Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J. Pharmacokinet. Pharmacodyn. 32 (2005) 485-500
43. Smith J., Wood E., and Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 21 (2004) 43-49
44. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., and Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178 (1999) 55-65
45. Brange J., Owens D.R., Kang S., and Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13 (1990) 923-954
46. Nucci G., and Cobelli C. Models of subcutaneous insulin kinetics. A critical review. Comput. Methods Programs Biomed. 62 (2000) 249-257
47. Miyazaki M., Mukai H., Iwanaga K., Morimoto K., and Kakemi M. Pharmacokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability. J. Pharm. Pharmacol. 53 (2001) 1235-1246
48. Bergman R.N. Minimal model: perspective from 2005. Horm. Res. 64 Suppl 3 (2005) 8-15
49. Natalucci S., Ruggeri P., Cogo C.E., Picchio V., and Burattini R. Insulin sensitivity and glucose effectiveness estimated by the minimal model technique in spontaneously hypertensive and normal rats. Exp. Physiol. 85 (2000) 775-781
50. Blondel O., and Portha B. Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. Diabetes Metab. 15 (1989) 382-387
51. Kasuga M., Akanuma Y., Iwamoto Y., and Kosaka K. Insulin binding and glucose metabolism in adipocytes of streptozotocin-diabetic rats. Am. J. Physiol. 235 (1978) E175-E182
52. Mathoo J.M., Shi Z.Q., Klip A., and Vranic M. Opposite effects of acute hypoglycemia and acute hyperglycemia on glucose transport and glucose transporters in perfused rat skeletal muscle. Diabetes 48 (1999) 1281-1288
53. Florea B.I., Thanou M., Junginger H.E., and Borchard G. Enhancement of bronchial octereotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J. Control. Release 110 (2006) 353-361